Detalles de la búsqueda
1.
Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Circulation
; 127(5): 624-33, 2013 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23307827
2.
Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension.
Health Qual Life Outcomes
; 11: 31, 2013 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23496856
3.
Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
J Clin Pharmacol
; 48(1): 19-25, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18094217
4.
Beraprost therapy for pulmonary arterial hypertension.
J Am Coll Cardiol
; 41(12): 2119-25, 2003 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-12821234
5.
Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.
J Clin Pharmacol
; 44(5): 503-9, 2004 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15102871
6.
Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension.
Pulm Circ
; 4(1): 45-52, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25006420
7.
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Chest
; 144(3): 952-958, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23669822
8.
The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension.
Chest
; 141(1): 36-42, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21659437
9.
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Chest
; 142(6): 1383-1390, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22628490
10.
Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
J Heart Lung Transplant
; 30(9): 982-9, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21531577
11.
Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.
J Heart Lung Transplant
; 29(2): 137-49, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20022264
12.
Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers.
J Cardiovasc Pharmacol
; 44(2): 209-14, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15243302
13.
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock.
Crit Care Med
; 32(1): 21-30, 2004 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-14707556
14.
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
J Cardiovasc Pharmacol
; 41(2): 293-9, 2003 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-12548091
Resultados
1 -
14
de 14
1
Próxima >
>>